Cambridge Investment Research Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,044	Closed	-$12K	–	3852
2025 Q3	$12K	Sell	10,044 -173,490	-95%	-$242K	﹤0.01%	3701
2025 Q2	$292K	Buy	+183,534	New	+$168K	﹤0.01%	3002
2023 Q4	–	Sell	-2,184	Closed	-$37K	–	3211
2023 Q3	$37K	Hold	2,184	–	–	﹤0.01%	3060
2023 Q2	$66K	Hold	2,184	–	–	﹤0.01%	3059
2023 Q1	$64K	Hold	2,184	–	–	﹤0.01%	3009
2022 Q4	$43K	Hold	2,184	–	–	﹤0.01%	2995
2022 Q3	$66K	Hold	2,184	–	–	﹤0.01%	2913
2022 Q2	$50K	Sell	2,184 -11	-0.5%	-$302	﹤0.01%	2942
2022 Q1	$98K	Hold	2,195	–	–	﹤0.01%	3012
2021 Q4	$85K	Buy	+2,195	New	+$99.6K	﹤0.01%	3051

Other funds holding CTXR

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Cambridge Investment Research Advisors's CTXR Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Citius Pharmaceuticals (CTXR) in Q4 2025, closing a stake of 10,044 shares — an estimated $12K sold.

Cambridge Investment Research Advisors first reported a position in CTXR in Q4 2021 and held it in 10 quarters. The position peaked at $292K in Q2 2025. 39 funds tracked by Wall St. Rank hold CTXR as of Q4 2025.

Cambridge Investment Research Advisors reported no remaining Citius Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 10,044 Citius Pharmaceuticals shares in Q4 2025, an estimated $12K.
Cambridge Investment Research Advisors first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Cambridge Investment Research Advisors's Citius Pharmaceuticals position peaked at $292K in Q2 2025.
39 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.